Literature DB >> 21334391

The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway.

Tali Lang1, Camden Lo, Narelle Skinner, Stephen Locarnini, Kumar Visvanathan, Ashley Mansell.   

Abstract

BACKGROUND & AIMS: Viruses target innate immune pathways to evade host antiviral responses. Recent studies demonstrate a relationship between hepatitis B disease states and the host's innate immune response, although the mechanism of immunomodulation is unknown. In humans, the innate immune system recognizes pathogens via pattern recognition receptors such as the Toll-like receptors (TLR), initiating anti-inflammatory responses. TLR expression and pro-inflammatory cytokine production is reduced in hepatitis B e antigen (HBeAg)-positive patients following TLR stimulation. The aim of this study was to investigate interactions between TLR signaling pathways and the mature HBeAg protein localized in the cytosol.
METHODS: The ability of HBeAg to inhibit TLR signaling and association with TLR adapters was evaluated by immunoprecipitation, immunostaining, and reporter studies.
RESULTS: Our findings show that HBeAg co-localizes with Toll/IL-1 receptor (TIR)-containing proteins TRAM, Mal, and TLR2 at the sub-cellular level, which was not observed for Hepatitis B core antigen. Co-immunoprecipitation analysis demonstrated HBeAg interacted with TIR proteins Mal and TRAM, while a mutated HBeAg ablated interaction between Mal and MyD88. Importantly, HBeAg also disrupted homotypic TIR:TIR interaction critical for TLR-mediated signaling. Finally, HBeAg suppressed TIR-mediated activation of the inflammatory transcription factors, NF-κB and Interferon-β promoter activity.
CONCLUSIONS: Our study provides the first molecular mechanism describing HBeAg immunomodulation of innate immune signal transduction pathways via interaction and targeting of TLR-mediated signaling pathways. These finding suggest the mechanism as to how HBeAg evades innate immune responses contributing to the pathogenesis of chronic hepatitis B infection and the establishment of viral persistence. Crown
Copyright © 2011. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21334391     DOI: 10.1016/j.jhep.2010.12.042

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  73 in total

1.  In vitro replication phenotype of a novel (-1G) hepatitis B virus variant associated with HIV co-infection.

Authors:  Liza M Cabuang; Tim Shaw; Margaret Littlejohn; Danni Colledge; Vitini Sozzi; Sally Soppe; Nadia Warner; Alex Thompson; Scott Preiss; Natasha Lam; Renae Walsh; Sharon R Lewin; Chloe L Thio; Gail Matthews; Stephen A Locarnini; Peter A Revill
Journal:  J Med Virol       Date:  2012-08       Impact factor: 2.327

2.  Hepatitis B e Antigen Inhibits NF-κB Activity by Interrupting K63-Linked Ubiquitination of NEMO.

Authors:  Yuan Wang; Lei Cui; Guifang Yang; Jianbo Zhan; Liang Guo; Yu Chen; Chengpeng Fan; Dan Liu; Deyin Guo
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

Review 3.  Global strategies are required to cure and eliminate HBV infection.

Authors:  Peter Revill; Barbara Testoni; Stephen Locarnini; Fabien Zoulim
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-24       Impact factor: 46.802

Review 4.  Interplay between hepatitis B virus and the innate immune responses: implications for new therapeutic strategies.

Authors:  Jieliang Chen; Zhenghong Yuan
Journal:  Virol Sin       Date:  2014-01-20       Impact factor: 4.327

Review 5.  Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance.

Authors:  Catherine Mn Croagh; Paul V Desmond; Sally J Bell
Journal:  World J Hepatol       Date:  2015-03-27

6.  New horizon for radical cure of chronic hepatitis B virus infection.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Hepatol       Date:  2016-07-28

Review 7.  Treatment of hepatitis B virus: an update.

Authors:  Haley Ward; Lydia Tang; Bhawna Poonia; Shyam Kottilil
Journal:  Future Microbiol       Date:  2016-11-18       Impact factor: 3.165

Review 8.  Mechanisms of Hepatitis B Virus Persistence.

Authors:  Kuen-Nan Tsai; Cheng-Fu Kuo; Jing-Hsiung James Ou
Journal:  Trends Microbiol       Date:  2017-08-16       Impact factor: 17.079

Review 9.  Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential.

Authors:  Maura Dandri; Joerg Petersen
Journal:  Clin Infect Dis       Date:  2016-06-01       Impact factor: 9.079

Review 10.  Regulation of microRNA by hepatitis B virus infection and their possible association with control of innate immunity.

Authors:  Xia Jiang; Tatsuo Kanda; Shuang Wu; Masato Nakamura; Tatsuo Miyamura; Shingo Nakamoto; Arup Banerjee; Osamu Yokosuka
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.